Sixera Pharma | Developing treatments for Netherton syndrome
14871
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-14871,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-13.6,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.5,vc_responsive

WHAT SIXERA PHARMA DOES

Sixera Pharma is a biopharmaceutical company based at the Karolinska Institute Science Park in Stockholm. The company was founded to develop basic research findings into treatments for skin diseases.

 

The founders of Sixera Pharma discovered key genes and the mechanisms regulating skin formation and barrier functions critical for the Netherton syndrome. The discovery resulted in the development of a new treatment of the disease, which is of great importance as no targeted treatment is available for the disease today. The new treatment is expected to drastically improve the quality of life for Netherton patients, which is an extremely vulnerable group of patients.

The clinical development of the treatment is carried out through a network of academic and industrial collaborations backed up by comprehensive pre-clinical work, along with development of regulatory documentation

WHAT’S NEW

Curious about our work?

 

At the news page you will find the latest information about our current work and the project’s most recent findings. Click the button below to explore more!

DO YOU WANT TO KNOW MORE? DON’T HESITATE TO CONTACT US!